TKPHF
Price
$29.31
Change
+$1.11 (+3.94%)
Updated
Sep 24 closing price
Capitalization
47.5B
ZTS
Price
$143.47
Change
+$2.34 (+1.66%)
Updated
Sep 26, 01:35 PM (EDT)
Capitalization
62.55B
39 days until earnings call
Interact to see
Advertisement

TKPHF vs ZTS

Header iconTKPHF vs ZTS Comparison
Open Charts TKPHF vs ZTSBanner chart's image
Takeda Pharmaceutical
Price$29.31
Change+$1.11 (+3.94%)
Volume$66.39K
Capitalization47.5B
ZOETIS
Price$143.47
Change+$2.34 (+1.66%)
Volume$1.2K
Capitalization62.55B
TKPHF vs ZTS Comparison Chart in %
Loading...
TKPHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TKPHF vs. ZTS commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TKPHF is a Buy and ZTS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (TKPHF: $29.31 vs. ZTS: $141.13)
Brand notoriety: TKPHF: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TKPHF: 95% vs. ZTS: 100%
Market capitalization -- TKPHF: $47.5B vs. ZTS: $62.55B
TKPHF [@Pharmaceuticals: Generic] is valued at $47.5B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $62.55B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TKPHF’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).

  • TKPHF’s FA Score: 2 green, 3 red.
  • ZTS’s FA Score: 2 green, 3 red.
According to our system of comparison, both TKPHF and ZTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TKPHF’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).

  • TKPHF’s TA Score: 5 bullish, 3 bearish.
  • ZTS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, TKPHF is a better buy in the short-term than ZTS.

Price Growth

TKPHF (@Pharmaceuticals: Generic) experienced а +3.94% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -4.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.88%. For the same industry, the average monthly price growth was +23.85%, and the average quarterly price growth was +67.10%.

Reported Earning Dates

ZTS is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($62.5B) has a higher market cap than TKPHF($47.5B). TKPHF has higher P/E ratio than ZTS: TKPHF (50.60) vs ZTS (24.29). TKPHF YTD gains are higher at: 9.570 vs. ZTS (-12.533). TKPHF has higher annual earnings (EBITDA): 1.13T vs. ZTS (4.02B). TKPHF has more cash in the bank: 419B vs. ZTS (1.44B). ZTS has less debt than TKPHF: ZTS (6.79B) vs TKPHF (4.51T). TKPHF has higher revenues than ZTS: TKPHF (4.48T) vs ZTS (9.39B).
TKPHFZTSTKPHF / ZTS
Capitalization47.5B62.5B76%
EBITDA1.13T4.02B27,992%
Gain YTD9.570-12.533-76%
P/E Ratio50.6024.29208%
Revenue4.48T9.39B47,736%
Total Cash419B1.44B29,199%
Total Debt4.51T6.79B66,353%
FUNDAMENTALS RATINGS
TKPHF vs ZTS: Fundamental Ratings
TKPHF
ZTS
OUTLOOK RATING
1..100
3053
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8919
PRICE GROWTH RATING
1..100
6064
P/E GROWTH RATING
1..100
2885
SEASONALITY SCORE
1..100
8575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TKPHF's Valuation (5) in the null industry is in the same range as ZTS (33) in the Pharmaceuticals Generic industry. This means that TKPHF’s stock grew similarly to ZTS’s over the last 12 months.

TKPHF's Profit vs Risk Rating (100) in the null industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that TKPHF’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for TKPHF (89) in the null industry. This means that ZTS’s stock grew significantly faster than TKPHF’s over the last 12 months.

TKPHF's Price Growth Rating (60) in the null industry is in the same range as ZTS (64) in the Pharmaceuticals Generic industry. This means that TKPHF’s stock grew similarly to ZTS’s over the last 12 months.

TKPHF's P/E Growth Rating (28) in the null industry is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that TKPHF’s stock grew somewhat faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TKPHFZTS
RSI
ODDS (%)
Bearish Trend 1 day ago
54%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
55%
Momentum
ODDS (%)
Bearish Trend 1 day ago
47%
Bearish Trend 1 day ago
65%
MACD
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
55%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
47%
Bearish Trend 1 day ago
58%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 1 day ago
59%
Advances
ODDS (%)
N/A
Bullish Trend 22 days ago
56%
Declines
ODDS (%)
N/A
Bearish Trend 1 day ago
57%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
58%
Aroon
ODDS (%)
Bullish Trend 1 day ago
50%
Bearish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
TKPHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GGME64.29-0.07
-0.11%
Invesco Next Gen Media and Gaming ETF
MRCP31.01-0.04
-0.13%
PGIM S&P 500 Buffer 12 ETF - Mar
EWY79.89-0.15
-0.19%
iShares MSCI South Korea ETF
HQL14.35-0.03
-0.21%
abrdn Life Sciences Investors
EWO30.85-0.17
-0.55%
iShares MSCI Austria ETF

TKPHF and

Correlation & Price change

A.I.dvisor tells us that TKPHF and TAK have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TKPHF and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TKPHF
1D Price
Change %
TKPHF100%
N/A
TAK - TKPHF
27%
Poorly correlated
-2.07%
TEVJF - TKPHF
17%
Poorly correlated
+39.73%
ZTS - TKPHF
16%
Poorly correlated
-0.38%
BHC - TKPHF
15%
Poorly correlated
-2.86%
QNTM - TKPHF
13%
Poorly correlated
-0.35%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with VTRS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-0.38%
VTRS - ZTS
47%
Loosely correlated
-2.27%
ELAN - ZTS
46%
Loosely correlated
+0.91%
PAHC - ZTS
41%
Loosely correlated
-0.55%
HLN - ZTS
38%
Loosely correlated
-1.69%
AMRX - ZTS
38%
Loosely correlated
-1.13%
More